Overview

Phase II Study of TAK228 in Relapsed Lymphoma

Status:
Terminated
Trial end date:
2018-07-10
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if TAK-228 can help to control relapsed lymphoma. The safety of this drug will also be studied.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Takeda